Mahamaya Lifescience

Q: How strong is Mahamaya Lifescience balance sheet?

Balance sheet of Mahamaya Lifescience is strong.But short term working capital might become an issue for this company.

Q: Is the debt of Mahamaya Lifescience increasing or decreasing?

Yes, The net debt of Mahamaya Lifescience is increasing.Latest net debt of Mahamaya Lifescience is ₹51.34 Crs as of Mar-26.This is greater than Mar-25 when it was ₹50.51 Crs.

Q: Is Mahamaya Lifescience stock expensive?

Mahamaya Lifescience is not expensive.Latest PE of Mahamaya Lifescience is 24.91, while 3 year average PE is 27.62. Also latest EV/EBITDA of Mahamaya Lifescience is 10.02 while 3yr average is 13.18.

MAHALIFE

Price

-- --

Nano Cap

₹419 Cr.

New to Zerodha? Sign-up for free.

Mahamaya Lifesciences manufactures pesticide formulations and supplies bulk formulations for Indian agrochemical companies and multinational corporations (MNCs). Initially focused on importing and registering critical pesticide molecules (Technical) not produced domestically, it conducted extensive product research before submitting registrations to the Central Insecticides Board and Registration Committee (CIBRC). Upon approval, it marketed these molecules as technical and value-added end-use formulations. Less

Mahamaya Lifesciences manufactures pesticide formulations and supplies bulk formulations for Indian… More

Low

111

52W Range

High

205

25.36

Sector PE

20.05

P/B

Div.Yield

ROE

26.19%

EBIDTA

10.17

ROCE

43.18

EPS

New to Zerodha? Sign-up for free.

Get instant stock alerts

Share Price
Financials
Revenue mix
Shareholdings
Peers
Forensics

Coming soon

Summary
Profit & Loss
Balance sheet
Cashflow

Yearly | Quarterly

View Detailed Summary

This data is currently unavailable for this company.

Yearly | Quarterly

(In Cr.)

(In Cr.)
This data is currently unavailable for this company.

Financial Ratio's

(In %)

Detailed P&L Report

(In Cr.)

Detailed Balance Sheet

Financial Year (In Cr.)

Detailed Cash Flow

Product wise
Location wise

MAHALIFE
Revenue Mix

Latest

Historic

This data is currently unavailable for this company.

MAHALIFE
Revenue Mix

Latest

Historic

This data is currently unavailable for this company.

More Info

Shareholdings

Holders

Detailed Shareholdings

This data is currently unavailable for this company.

Peers

Detailed Peers

Forensics

View Detailed Forensics

Recent events

News
Corporate Actions

Leadership Transition

Aug 25, 2026

Mahamaya Lifesciences approved a succession in which managing director Krishnamurthy Ganesan was to become chairman and executive non-independent director from November 1, 2026. Prashant Krishnamurthy was to resign as chief financial officer on October 31 and become managing director from November 1, while Amarendra Mohapatra was appointed CFO. The board also appointed Bhagirath Choudhary as an independent director and renewed the terms of Gopal Krishna Raju and Charudatta Digambar Mayee. It appointed Kush Mishra as company secretary and compliance officer and approved the notice for the September 29 annual general meeting. Mahamaya generated consolidated revenue of about ₹329 crore in FY26; manufacturing and formulations accounted for roughly 40-50% of sales, with technical and active-ingredient trading making up the balance. Operating cash flow for FY26 was negative, while inventory stood at ₹141 crore and receivables at ₹71 crore.

Mahamaya Lifesciences Names Amarendra Mohapatra As CFO

Aug 25, 2026

Events:

Annual Report

Announcement Date

Sep 07, 2026

Quarterly Results

Announcement Date

May 25, 2026

Lockin Period Expiry (Non-Promoter)

Date

May 18, 2026

Lockin Period Expiry (Anchor)

Date

Feb 11, 2026

Lockin Period Expiry (Anchor)

Date

Dec 13, 2025

Quarterly Results

Announcement Date

Dec 02, 2025

More Nano Cap Ideas

See similar 'Nano' cap companies with recent activity

Promoter Buying

Companies where the promoters are bullish

Detailed List

Capex

Companies investing on expansion

Detailed List

Superstar Investor

Companies where well known investors have invested

Detailed List

Popular questions

Business
Financials
Share Price
Shareholdings

What does Mahamaya Lifescience do?

Mahamaya Lifesciences specializes in the manufacturing of pesticide formulations and supply bulk formulations catering to both Indian agrochemical companies, as well as multinational corporations (MNCs). It began its journey by focusing on import and registration of vital pesticide molecules (Technical) that were not produced domestically in India. It imported these molecules after lot of product research and worked on registering them with the Central Insecticides Board and Registration Committee (CIBRC) under the Department of Agriculture, Government of India. After successful registration it marketed these molecules both as technical and as value added end use formulations for both domestic manufacturers and MNCs.

Who are the competitors of Mahamaya Lifescience?

Mahamaya Lifescience major competitors are Nova Agritech, Bhagiradha Chemicals, Dharmaj Crop Guard, Bayer CropScience, UPL, Super Crop Safe, 3B Blackbio Dx. Market Cap of Mahamaya Lifescience is ₹418 Crs. While the median market cap of its peers are ₹1,112 Crs.

Is Mahamaya Lifescience financially stable compared to its competitors?

Mahamaya Lifescience seems to be less financially stable compared to its competitors. Altman Z score of Mahamaya Lifescience is 3.44 and is ranked 5 out of its 8 competitors.

Does Mahamaya Lifescience pay decent dividends?

The company seems to be paying a very low dividend. Investors need to see where the company is allocating its profits. Mahamaya Lifescience latest dividend payout ratio is 0% and 3yr average dividend payout ratio is 0%

How has Mahamaya Lifescience allocated its funds?

Companies resources are allocated to majorly unproductive assets like Inventory

How strong is Mahamaya Lifescience balance sheet?

Balance sheet of Mahamaya Lifescience is strong. But short term working capital might become an issue for this company.

Is the profitablity of Mahamaya Lifescience improving?

Yes, profit is increasing. The profit of Mahamaya Lifescience is ₹16.52 Crs for TTM, ₹12.94 Crs for Mar 2025 and ₹5.22 Crs for Mar 2024.

Is the debt of Mahamaya Lifescience increasing or decreasing?

Yes, The net debt of Mahamaya Lifescience is increasing. Latest net debt of Mahamaya Lifescience is ₹51.34 Crs as of Mar-26. This is greater than Mar-25 when it was ₹50.51 Crs.

Is Mahamaya Lifescience stock expensive?

Mahamaya Lifescience is not expensive. Latest PE of Mahamaya Lifescience is 24.91, while 3 year average PE is 27.62. Also latest EV/EBITDA of Mahamaya Lifescience is 10.02 while 3yr average is 13.18.

Has the share price of Mahamaya Lifescience grown faster than its competition?

There is not enough historical data for the companies share price.

Is the promoter bullish about Mahamaya Lifescience?

Promoters stake in the company seems stable, and we need to go through filings and allocation of resources to gauge promoter bullishness. Latest quarter promoter holding in Mahamaya Lifescience is 56.35% and last quarter promoter holding is 56.35%.

Are mutual funds buying/selling Mahamaya Lifescience?

There is Insufficient data to gauge this.

Mahamaya Lifescience

Share Price

Financials

Summary

Profit & Loss

Balance sheet

Cashflow

Revenue mix

Product wise

Location wise

Shareholdings

Peers

Forensics

Recent events

News

Corporate Actions

More Nano Cap Ideas

Promoter Buying

Capex

Superstar Investor

Popular questions

What does Mahamaya Lifescience do?

Who are the competitors of Mahamaya Lifescience?

Is Mahamaya Lifescience financially stable compared to its competitors?

Does Mahamaya Lifescience pay decent dividends?

How has Mahamaya Lifescience allocated its funds?

How strong is Mahamaya Lifescience balance sheet?

Is the profitablity of Mahamaya Lifescience improving?

Is the debt of Mahamaya Lifescience increasing or decreasing?

Is Mahamaya Lifescience stock expensive?

Has the share price of Mahamaya Lifescience grown faster than its competition?

Is the promoter bullish about Mahamaya Lifescience?

Are mutual funds buying/selling Mahamaya Lifescience?